Evidence map›Paper›PMID 42397842›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Covalently PD-L1 Anchoring Drives Bispecific Nanostructure Assembly for Spatial Control of T Cell Recruitment and Activation.

Fengzhen Zhang, Yuhan Dong, Kailu Liu, Hui Hu, Huimin Chang, Jianli Zuo, Xuedan Ma, Jie Xu, Yongjun Dang, Xiaobo Wang and 1 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fengzhen ZhangDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Yuhan DongDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Kailu LiuDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Hui HuDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Huimin ChangDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Jianli ZuoDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.ORCID 0009-0004-8781-5532
Xuedan MaDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Jie XuDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.
Yongjun DangDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.ORCID 0000-0001-7237-1132
Xiaobo WangDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.ORCID 0009-0001-3226-6247
Hongwen LiangDepartment Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, College of Pharmacy, Ministry of Education, Chongqing Medical University, Chongqing, China.ORCID 0000-0002-8110-8085

Funding

BAYU Scholar Program YS2025025Chongqing Medical University YXY2024JBGS04Chongqing Medical University YXY2024JBGSS03Chongqing Natural Science Foundation CSTB2023NSCQ-MSX0314National Key Research and Development Program of China 2022YFC2804800National Natural Science Foundation of China 22507017Scientific and Technological Research Program of Chongqing Municipal Education Commission KJQN202400414Scientific and Technological Research Program of Chongqing Municipal Education Commission KJZD-K202500404
6 · The paper itself

Abstract

Immune checkpoint blockades have shown great potential in cancer therapy. However, achieving efficient recruitment and activation of T cells while blocking immune suppression remains a critical challenge. Current strategies mainly focus on the blockade of the PD-1/PD-L1 axis, with limited attention to reprogramming immune functions on the tumor cell surface. Here, we report a "localized oxidation-covalent assembly" strategy that achieves precise modification of PD-L1 on the cell surface through glycan oxidation, thereby harnessing bioorthogonal reactions to induce the in situ construction of artificial topological nanostructures (ATNs), which subsequently augment T cell-mediated antitumor immunity. ATNs not only block the PD-1/PD-L1 axis to relieve immune suppression but also recruit and activate T cells through transmembrane bridging interactions, mimicking bispecific T cell engagers (BiTEs) and markedly enhancing antitumor immune responses. Mechanistic studies revealed that N-glycosylation sites are critical for probe-mediated aldehyde modification of PD-L1. We further demonstrated that the ATNs achieve spatially precise T cell recruitment and activation via PD-L1-dependent localization, enabling programmable immune regulation. Overall, this approach not only underscores the potential of glycan oxidation-driven self-assembly in immune modulation but also provides a versatile chemical biology tool for the precise reprogramming of immune checkpoint functions.

Indexed as

B7-H1 AntigenNanostructuresT-LymphocytesAnimalsGlycosylationHumansLymphocyte ActivationOxidation-ReductionPolysaccharidesB7-H1 AntigenCD274 protein, humanPolysaccharidesglycan oxidationimmunotherapynanostructurePD‐L1peptideself‐assembly

Identifiers

PMID42397842
PMCPMC13549062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.